RA Capital Management

RA Capital Management joined 74 recorded rounds in the last two years (28 in the last 12 months), down from 117 in the two years before. By year: 11 in 2026, 46 in 2025 and 76 in 2024. Across all 251 recorded rounds, 109 were later-stage, 70 were early-stage and 10 were seed. 2 rounds landed in the last 90 days. RA Capital Management most often invests alongside Fidelity Management & Research Company (12 shared rounds) and Viking Global Investors (10 shared rounds). Most recently: Superluminal Medicines (Series B, Sep 2026) and Expedition Therapeutics (Series B, Aug 2026).